TGFB1 and pulmonary fibrosis: Idiopathic pulmonary fibrosis treatment is now based on the use of either pirfenidone, an agent that reduces TGF‐β signalling pathway and it has also anti‐inflammatory actions 30, or nintedanib, a tyrosine kinase inhibitor able to reduce the transduction pathway of a number of growth factor receptors, and to reduce the transduction pathways leading to cell activation and proliferation 4.